Wyniki wyszukiwania

1

Bicistronic strategy for angiogenic gene therapy

100%

Malecki M., Przybyszewska M., Janik P.

Acta Biochimica Polonica

|

2003

|

tom 50

|

nr Supplement 1

2

In vitro and in vivo study of the expression vector encoding vascular endothelial growth factor

100%

Malecki M., Przybyszewska M., Janik P.

Archivum Immunologiae et Therapiae Experimentalis

|

2001

|

tom 49

|

nr 3

243-246

3

Rola przejścia epitelialno-mezenchymalnego w progresji nowotworu

100%

Gos M., Miloszewska J., Przybyszewska M.

Postępy Biochemii

|

2009

|

tom 55

|

nr 2

4

Escape from contact inhibition as a result of signal transduction disorder

100%

Janik P., Miloszewska J., Przybyszewska M.

Cellular and Molecular Biology Letters

|

2002

|

tom 07

|

nr Suppl.

5

Construction of a bicistronic proangiogenic expression vector and its application in experimental angiogenesis in vivo

100%

Malecki M., Przybyszewska M., Janik P.

Acta Biochimica Polonica

|

2003

|

tom 50

|

nr 3

Manipulation of angiogenesis in vivo is an example of successful gene therapy strategies. Overexpression of angiogenic genes like VEGF, FGF or PDGF causes new vessel formation and improves the clinical state of patients. Gene therapy is a very promising procedure but requires large amounts of pharmaceutical-grade plasmid DNA. In this regard we have constructed a bicistronic plasmid DNA vector encoding two proangiogenic factors, VEGF165 and FGF-2. The construct (pVIF) contains the internal ribosome entry site (IRES) of the encephalomyocarditis virus (ECMV) which permits both genes to be translated from a single bicistronic mRNA. The IRES sequence allows for a high efficiency of gene expression in vivo. The pVIF vector was characterized in vitro and in vivo. In vivo angiogenesis studies showed that the bicistronic vector encoding two proangiogenic factors induces the formation of new vessels significantly more than pVEGF165 or pFGF-2 alone. In our opinion the combined pro- angiogenic approach with VEGF165 and FGF-2 is more powerful and efficient than single gene therapy. We also postulate that IRES sequence can serve as a useful device improving efficiency of gene therapy.

6

The role of FNIII/10 and FNIII/10 RGD fibronectin ragments in contant inhibition of C3H10T1/2 cells

88%

Miloszewska J., Gos M., Trembacz H., Przybyszewska M., Janik P.

Acta Biochimica Polonica

|

2003

|

tom 50

|

nr Supplement 1

7

Cancer stem cells from mouse sarcoma cell line- L1: preliminary results

88%

Miloszewska J., Gos M., Przybyszewska M., Szaniawska B., Trembacz H.

Acta Biochimica Polonica

|

2006

|

tom 53

|

nr Supplement 1

8

Metastatic capacity stimulated by cancer cells cultivation in non-adhesive conditions

88%

Gos M., Miloszewska J., Trembacz H., Przybyszewska M., Janik P.

Acta Biochimica Polonica

|

2006

|

tom 53

|

nr Supplement 1

9

The role of focal adhesion kinase in the emigration of cells from confluent cultures

76%

Trembacz H., Miloszewska J., Szaniawska B., Malecki M., Przybyszewska M., Skorski T., Janik P.

Cellular and Molecular Biology Letters

|

2002

|

tom 07

|

nr 4

We studied the effect of the modification of focal adhesion kinase (FAK) on the growth, migration and adhesion of C3H 10T1/2 cells. Cells transfected with plasmid coding for antisense FAK displayed a low level of FAK protein. Interestingly, the transfected cells achieved a higher saturation density at confluence, and displayed reduced adhesion and enhanced emigration from a confluent layer of cells when stimulated with fibronectin. In conclusion, it can be postulated that FAK plays an important role in the mechanism of contact inhibition.

10

Soluble TNF-alpha receptor 1 encoded on plasmid vector and its application in experimental gene therapy of radiation-induced lung fibrosis

64%

Przybyszewska M., Miloszewska J., Rzonca S., Trembacz H., Pysniak K., Kotlarz A., Swoboda P., Zalewska M., Malecki M.

Archivum Immunologiae et Therapiae Experimentalis

|

2011

|

tom 59

|

nr 4

11

Imatinib inhibits the renewal and tumorigenicity of CT-26 colon cancer cells after cytoreductive treatment with doxorubicin

64%

Przybyszewska M., Miloszewska J., Kotlarz A., Swoboda P., Pysniak K., Szczepek W., Kaczmarek L., Markowicz S.

Archivum Immunologiae et Therapiae Experimentalis

|

2017

|

tom 65

|

nr 1

Ograniczanie wyników

5 Acta Biochimica Polonica

3 Archivum Immunologiae et Therapiae Experimentalis

2 Cellular and Molecular Biology Letters

1 Postępy Biochemii

11 Przybyszewska M.

8 Miloszewska J.

7 Janik P.

5 Malecki M.

5 Trembacz H.

4 Gos M.

2 Kotlarz A.

2 Pysniak K.

2 Swoboda P.

2 Szaniawska B.

1 Kaczmarek L.

1 Markowicz S.

1 Rzonca S.

1 Skorski T.

1 Szczepek W.

1 Zalewska M.

1 2017

1 2011

1 2009

2 2006

3 2003

2 2002

1 2001

Bicistronic strategy for angiogenic gene therapy

In vitro and in vivo study of the expression vector encoding vascular endothelial growth factor

Rola przejścia epitelialno-mezenchymalnego w progresji nowotworu

Escape from contact inhibition as a result of signal transduction disorder

Construction of a bicistronic proangiogenic expression vector and its application in experimental angiogenesis in vivo

The role of FNIII/10 and FNIII/10 RGD fibronectin ragments in contant inhibition of C3H10T1/2 cells

Cancer stem cells from mouse sarcoma cell line- L1: preliminary results

Metastatic capacity stimulated by cancer cells cultivation in non-adhesive conditions

The role of focal adhesion kinase in the emigration of cells from confluent cultures

Soluble TNF-alpha receptor 1 encoded on plasmid vector and its application in experimental gene therapy of radiation-induced lung fibrosis

Imatinib inhibits the renewal and tumorigenicity of CT-26 colon cancer cells after cytoreductive treatment with doxorubicin